IPN Share Price

Open 116.05 Change Price %
High 116.10 1 Day -1.75 -1.50
Low 114.30 1 Week 3.90 3.52
Close 114.65 1 Month 2.10 1.87
Volume 101957 1 Year 53.83 88.51
52 Week High 129.85
52 Week Low 60.33
IPN Important Levels
Resistance 2 116.32
Resistance 1 115.63
Pivot 115.02
Support 1 113.67
Support 2 112.98
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
HAV 9.26 0.11%
HAV 9.26 0.11%
More..
EPA France Top Gainers Stocks
MLLEM 1.00 42.86%
ALIMO 0.26 18.18%
ALDIE 1.29 17.27%
APAM 33.78 15.72%
APAM 33.78 15.72%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
More..
EPA France Top Losers Stocks
OXI 0.08 -11.11%
OXI 0.08 -11.11%
COH 2.97 -7.19%
COH 2.97 -7.19%
COH 2.97 -7.19%
COH 2.97 -7.19%
MLSAT 4.53 -6.79%
DPT 0.16 -5.88%
HBW 0.16 -5.88%
AVT 0.17 -5.56%
More..

Ipsen (EPA: IPN)

IPN Technical Analysis 3
As on 22nd Sep 2017 IPN Share Price closed @ 114.65 and we RECOMMEND Buy for LONG-TERM with Stoploss of 93.02 & Buy for SHORT-TERM with Stoploss of 111.94 we also expect STOCK to react on Following IMPORTANT LEVELS.
IPN Target for September
1st Target up-side 117.24
2nd Target up-side 120.31
3rd Target up-side 123.39
1st Target down-side 108.46
2nd Target down-side 105.39
3rd Target down-side 102.31
IPN Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.ipsen.com
IPN Address
IPN
65, quai Georges Gorse
Cedex
Boulogne-Billancourt, 92650
France
Phone: 33 1 58 33 50 00
Fax: 33 1 58 33 50 01
IPN Latest News
Interactive Technical Analysis Chart Ipsen ( IPN EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ipsen
IPN Business Profile
Ipsen S.A. operates as a pharmaceutical company worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The company’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen S.A. also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it provides Smecta, a natural clay-based drug used in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan that is used in the treatment of age-related cognitive disorders. Further, the company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing products in the areas of neurology, endocrinology, and uro-oncology, including BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.